• About
  • Subscribe
  • Advertise
  • Contact
Wednesday, July 16, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home

Perth partnership targets childhood blindness and $1 billion market

by Myles Hume
October 23, 2019
in Business, Company updates & acquisitions, Local, Macular disease, News, Ophthalmology, Research, Therapies
Reading Time: 3 mins read
A A
Share on FacebookShare on Twitter

The Lions Eye Institute (LEI) has signed a commercial partnership that will combine its antisense gene therapy for a leading cause of childhood blindness with a new Australian-developed drug delivery platform.

LEI and ASX-listed PYC Therapeutics have entered into a commercial collaboration agreement that will initially develop drugs to treat retinitis pigmentosa. The partnership sees the formation of a new Perth-based special purpose organisation called Vision Pharma, to which LEI and PYC have contributed equal levels of intellectual property.

Vision Pharma will combine PYC’s cell penetrating peptide (CPP) drug delivery technology with a proprietary LEI drug known as an antisense oligonucleotide (ASO). The ASO has already shown preliminary evidence of successfully reversing the effects of a genetic mutation in human cells associated with retinitis pigmentosa.

With no existing treatment options available for the disease, it is thought the therapy’s potential target market could top $1 billion per year.

The drug is currently in advanced pre-clinical development and is scheduled to enter investigational new drug-enabling studies during the first half of 2020. If successful, it will be approved for testing in humans.

“LEI is proud to see one of its research developments now entering pre-clinical trials to treat the commonest form of retinitis pigmentosa,” LEI managing director Professor Bill Morgan said.

“Professor Fred Chen (LEI) and Professor Sue Fletcher (formerly of Murdoch University) have been working on their genetic therapy and are partnering with PYC, using their transporter protein to deliver this novel therapy directly to the sick retinal cells. We are very excited about the possibility of being able to cure this form of blindness.”

Chen, co-inventor of the lead drug candidate and head of LEI’s Ocular Tissue Engineering Laboratory, said the agreement was the culmination of decades of splice therapy research. Now, this work is being combined with PYC’s CPPs, data from the Australian Inherited Retinal Diseases Registry and LEI’s expertise in stem cell retinal disease modelling.

“The advantage of using ASO is that it’s personalised medicine; specific for the gene or the mutation. Its delivery into the cell does not require the introduction of a viral vector into the eye and into the retinal cell where the transferred gene is not under the normal regulation, resulting in the potential for over or under production of the protein coded by the gene.

“ASO treatment is different from gene transfer therapy; it manipulates the way in which gene is processed and expressed a level downstream from the DNA – at the RNA level – where splicing occurs.

“We estimate that a third of the patients with inherited retinal disease may carry splice altering mutations that might be treatable with this method.”

According to PYC, its drug delivery technology addresses a major obstacle in precision medicine by being able to deliver precise and potent drugs to targets inside cells.

Vision Pharma is also developing a pipeline of other ASO candidates for the treatment of different forms of inherited retinal disease and expects to progress them into the clinic alongside the lead drug candidate.

PYC also announced that Fletcher, a global leader in the design and development of RNA therapeutics, has been appointed as chief of research and development on a part-time basis. She will be tasked with supporting both the retinitis pigmentosa program and building PYC’s pipeline of CPP-ASO drugs.

Tags: LEILions Eye InstituteophthalmologyPYC Therapeuticsretinitis pigmentosaVision Pharma

Related Posts

The optometry school is proposed for James Cook University. Image: EQRoy/Shutterstock.com.

New Queensland optometry school under consideration despite opposition

by Myles Hume
July 16, 2025

A new optometry school – which would be Australia’s eighth – is being proposed in North Queensland, as debate about...

The meeting – running for a third time – welcomed a record 560-plus delegates from 37 countries. Image: APSPOS.

APSPOS 2025 recap; dual Brisbane conference success for Think Business Events

by Staff Writer
July 15, 2025

The 3rd Congress of the Asia-Pacific Strabismus and Paediatric Ophthalmology Society (APSPOS), held in Brisbane from 29 June to 1...

Eye tests are just as important for people with diabetes, and KeepSight helps to facilitate these.  Image: Graphicroyalty/stock.adobe.com.

Report: KeepSight helping save vision of 560,000 Aussies

by Staff Writer
July 15, 2025

A newly released report shows that more than 560,000 Australians with diabetes are reducing their risk of blindness by over...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited